PK and Safety of IN-C004 (Tegoprazan ODT) in Healthy Volunteers

Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) (6 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area under the plasma concentration-time curve of tegoprazan from time zero to last measurable concentration at 48 hours, Maximum Plasma Concentration of tegoprazan at 48 hours and 2 more. Started Jan 2021; status: completed.